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Racial make-up has been identified as one of many risk factors for PC with 50% higher incidence and mortality rates among AA men than CA counterparts (1). Earlier onset of the disease, high disease volume, aggressive metastatic disease, and poor survival rate are evident among AA males (2, 3) . Although the disproportionate incidence and mortality cannot be fully explained by genetic, socioeconomic, and environmental factors (4, 5) , chromosome 8q24 has recently been implicated in susceptibility of AA men to PC (6, 7) . While a more biological aggressive phenotype has been proposed (8) , little attention was focused on unraveling the underlying molecular mechanisms involved in racial disparity of PC.
Aberrant expression of AR has long been implicated in initiation and development of castration-resistant prostate cancer (CRPC) (9) . Based on their physical interactions and ability to modulate transcription, a repertoire of intermediary transcriptional protein complexes (coactivators and corepressors) have been shown to be recruited by AR to modify chromatin and facilitate transcription of androgen-regulated genes (AGRs) in cell type-specific manner (10) . Notably, the differential expression and pathophysiological significance of these cofactors in CRPC in AA men has not been established. These facts argue that aberrant expression and/or function of AR and its coregulators may contribute to disease progression and emergence of CRPC in AA men.
As a residual scaffolding of the nucleus to which repeated DNA sequences and actively transcribed genes are anchored (11) , the nuclear matrix (NM), has recently sparked a surge of interest as being the molecular underpinning of cancer-specific markers (12) . The family of heterogeneous nuclear ribonucleoproteins (hnRNPs) has more than 30 members of ubiquitously expressed NM proteins (13) . hnRNPs complex with heterogeneous nuclear RNA (hnRNA) and modulate pre-mRNA biogenesis, metabolism, and transport (14) . The hnRNP H/F is subfamily of hnRNPs encoded by different genes into subtype-naïve forms, including hnRNP H (hnRNP H1), hnRNP H' (hnRNP H2), hnRNP F, and hnRNP 2H9 (15) . These proteins possess a modular and highly conserved structure encompassing two glycine-rich auxiliary domains and two or three repeats of RNA binding domain termed quasi-RNA recognition motif (qRRM). The hnRNP H/F members bind in concert to cognate G-rich intronic and exonic sequences in close proximity to the polyadenylation site to regulate both inhibitory and stimulatory alternative splicing of target genes (16) . As a bona fide component of the NM, (17) , the functional significance of hnRNP H1 is relatively unknown and only recently has evidence emerged related to its biological function. Although hnRNP H1 has been shown to be expressed in a number of human cancers (18) , its functional significance in cancer development and/or progression has not been elucidated. The rapid reduction of hnRNP H1 transcripts in cells undergoing differentiation (19) underscores a potential role for this NM protein in tumor cell differentiation.
In the present study we identified by an in vivo functional genomics approach, encompassing a combined in tandem approach of LCM, SSH and custom cDNA microarray comparative analyses, the differential expression of hnRNP H1 in prostate tumor cells of AA men and further characterized its functional role in cell growth and development of therapeutic resistance through transcriptional regulation and activation of AR in hormone dependent and independent manner.
Body:

Task-1: To examine if hormone receptors mediate hnRNPH1 and SAFB2 induced growth and metastasis of PC cells in vitro. (Months 1-12).
1-1: siRNA silencing or ectopic expression strategies to determine if SAFB2 and/or hn-RNP-H1 gene(s) will modulate growth, colony-forming ability, cell cycle characteristics, and viability of AA-derived E006AA, MDA-PCa2a CaP cells, and CS-derived PC-3 and LNCaP CaP cells.
hnRNP H1 siRNA-silencing induces growth arrest and sensitizes AR-expressing prostate cancer cellss to Bicalutamide: We tested the hypothesis that hnRNPH1, a differentially expressed gene in prostate tumors of AA men, is involved in disease progression in this ethnic group of patients. Initially we demonstrated that the basal transcript expression levels of hnRNP H1 was 3-and 6-fold higher (p<0.01) in AR-expressing MDA-PCa-2b and C4-2B cells, respectively, with predominant nuclear localization compared to the AR naïve PC-3 cells ( Figure 1, A and B) . The selective expression of hnRNP H1 in ARexpressing cells was further corroborated by tissue microarray IHC analysis where higher nuclear immunostaining was observed in LNCaP cells ( Figure 8L ) compared to PC-3 cells ( Figure 8K ). Accordingly, MDA-PCa-2b and C4-2B cells were then exploited as a model to unravel the functional significance of hnRNP H1 in the AR-mediated prostate tumor cell growth and drug resistance. hormone resistance through activation of AR in PC cells. A) qRT-PCR analysis of hnRNP H1 in AR-expressing (C4-2B and MDA-PCa-2B) and AR-naïve PC-3 cells. B) ICC analysis of hnRNP H1 in MDA-PCa-2b cells. C and D) Optimization of siRNA silencing and transfection efficiencies in PC cells by GFP and siGLO Lamin A/C. E and F) Endogenous mRNA and proteins levels of hnRNP H1, respectively, at 24 hr following siRNA transfection. G) Assessment of growth inhibitory effects by a cell counting assay kit in hnRNP H1 siRNA-silenced MDA-PCa-2b cells cultured in complete medium for up to 120 hr. H and I) Cell growth of MDA PCa-2b and C4-2B cells, respectively, pre-transfected with siControl or hnRNP H1 siRNA and cultured in RPMI containing charcoal-stripped serum and various concentrations of BIC with (+) or without (-) DHT for 24 hr (n=3). J and K) COS-7 and CV-1 cells, respectively, were cultured in charcoal-stripped FBS medium in absence (ethanol) or presence of DHT and co-transfected with hnRNP H1, pCMV-AR, and psPSA-Luc plasmids. L) C4-2B cells co-transfected with hnRNP H1 and psPSA-Luc plasmids and cultured with or without DHT. M) C4-2B cells co-transfected with siControl or siRNPH1 and psPSA-Luc reporter and cultured with or without DHT. For normalization all cells were co-transfected with 5 ng pRL-SV40. Activity was measured with dual luciferase system and the results were expressed as fold change of relative light units (RLU). * and ** denotes significant difference at p<0.05 and p<0.01, respectively, in comparison to controls (n=3). Next, we examined by siRNA strategy whether hnRNP H1 is critical to proliferation of MDA-PCa-2b and PC-3 cells. Transfection, as optimized by GFP and siGLO Lamin A/C duplex siRNA, demonstrates > 95% transfection and silencing efficiencies in both cell lines ( Figure 1 , C and D). The hnRNP H1 siRNA down-regulated the target gene by at least 90% as opposed to cells transfected with non-targeting siControl duplexes (Figure 1, E and F). As shown in Figure  1G , a significant (p<0.05) time-dependent growth inhibition was observed as early as 48 hr in MDA-PCa-2b cells transfected with hnRNP H1 siRNA in comparison to untrasfected or siControl transfected cells. In contrast, the growth kinetics was not affected in response to target gene silencing in AR-naïve PC-3 cells under similar experimental conditions (data not shown).
Since androgen deprivation is the mainstay therapy for locally advanced and CRPC, we sought to examine whether modulation of endogenous hnRNP H1 levels would impact the sensitivity and/or therapeutic efficacy of the non-steroidal anti-androgen BIC in PC cells. MDA-2B-PCa and C4-2B cells pre-transfected with hnRNP H1 siRNA or siControl were subjected to various concentration of BIC in presence of dihydrotestosterone (DHT) or vehicle control. hnRNP H1 siRNA-silenced MDA-PCa-2b and C4-2B cells were sensitive to BIC cytotoxicity at 10 µM in absence and presence of DHT in cells (p<0.05) ( Figure 1 , H and I), suggesting a role for this NM protein in development of antiandrogen drug resistance.
1-2: Effects of target genes in modulating hormone receptor gene expression by qRT-PCR and western blot analysis.
hnRNP H1 Interacts with AR and Regulates Transcription of AR and PSA in PC Cells. We tested the hypothesis that the nuclear matrix protein hnRNPH1is involved in transcriptional regulation of androgen receptor (AR) and its target gene PSA. Based on its role in mRNA biogenesis and AR interaction, we examined if endogenous expression of hnRNP H1 modulates transcriptional regulation of AR and ARGs in AR-expressing PC cells. qRT-PCR analysis reveals that siRNA silencing of hnRNP H1 (Figure 2A , and AR (E and F) transcripts in MDA-PCa-2b and C4-2B cells, respectively, cultured in phenol red-free, charcoalstripped media and transfected with siControl (non-target siRNA) or hnRNP H1 siRNA (siRNP H1) with or without DHT (n=3). Immunoblot analysis of PSA, AR and hnRNP H1 in hnRNP H1 siRNA-silenced (siRNPH1) or siControl-transfected MDA-PCa-2b (G) and C4-2B (H) cells, respectively, with or without DHT. The purity of nuclear and cytoplasmic fractions was assessed by TATA binding protein (TBP) and α-tubulin, respectively, whereas actin was used as a loading control (n=3). * and ** denotes statistical significant difference at p<0.05 and p<0.01, respectively. These findings were confirmed by immunoblot analysis (Figure 2 , G and H). In contrast, DHT increased nuclear hnRNP H1 protein levels in both cell lines ( Figure  3 , G and H), suggesting a positive feedback regulatory loop between androgens and hnRNP H1 in the transcriptional regulation of AR and PSA genes in PC cells.
1-3 and 1-4: Effect of target genes on regulating promoter activities of hormone receptors (AR, ER) using reporter assays, EMSA and ChIP assays.
We tested the hypothesis that hnRNPH1 binds AR and enhances its transactivation in prostate cancer cells.
hnRNP H1 Confers Androgen Dependent and Independent Transactivation of the AR in PC Cells.
The growth inhibitory effects caused by hnRNP H1 siRNA silencing in MDA-PCa-2b cells prompted us to investigate whether these effects are mediated through modulation of AR activation. As shown in Figures 4A and 4B , hnRNP H1 induced hormone-independent AR activation in AR-transfected COS-7 and CV-1 cells when compared to negative controls or cells transfected with wtAR or hnRNP H1 alone (p<0.05). Likewise, transfection of C4-2B cells with hnRNP H1 caused AR transactivation in a ligand-independent manner ( Figure 4C ). In contrast, DHT induced almost twice the level of AR activation following ectopic co-expression of hnRNP H1 and AR in COS-7 and CV-1 cells ( Figure 4A and B, respectively) and hnRNP H1-transfected C4-2B cells ( Figure 4C ) as opposed either factor alone (p<0.05). Interestingly, DHT in absence of AR significantly increased (p<0.05) PSA promoter activity in hnRNP H1-transfected COS-7 and CV-1 cells. Finally, these findings were confirmed by silencing hnRNP H1 in MDA-C4-2B cells with or without DHT ( Figure 4D ). and CV-1 (B) cells, respectively, were cultured in charcoalstripped FBS medium in absence (ethanol) or presence of DHT and cotransfected with hnRNP H1, pCMV-AR, and psPSA-Luc plasmids. C) C4-2B cells co-transfected with hnRNP H1 and psPSA-Luc plasmids and cultured with or without DHT. D) C4-2B cells cotransfected with siControl or siRNPH1 and psPSA-Luc reporter and cultured with or without DHT. For normalization all cells were co-transfected with 5 ng pRL-SV40. Activity was measured with dual luciferase system and the results were expressed as fold change of relative light units (RLU). * and ** denotes significant difference at p<0.05 and p<0.01, respectively, in comparison to controls (n=3).
hnRNP H1 physically interacts with AR in PC Cells. The activation of AR by hnRNP H1 prompted us to investigate if these proteins physically interact in PC cells. Analysis of PC cell lysates immunoprecipitated (IP) with anti-hnRNP H1 demonstrates an increase in immunoblotted AR levels ( Figure 5A ). Conversely, immunoblotted hnRNP H1 increased in cell lysates reciprocally IP with AR antibody in comparison to control rabbit IgG, suggesting protein-protein interaction. The AR-hnRNP H1 interaction was further augmented in DHT-treated cells ( Figure  5B ). Immunocytochemical analysis demonstrated that the interacting proteins are primarily colocalized in the nucleus even in the absence of DHT, an effect that was enhanced by of DHT ( Figure 6C ).
Figure 5 (above)
. AR-hnRNP H1 physically interact with AR PC Cells. A) PC cell lysates cultured in complete medium were subjected to immunoprecipitation (IP) using anti-AR or anti-hnRNP H1 antibody, followed by immunoblotting (IB) with the indicated antibodies in a reversed order as shown. B) Lysates of PC cells cultured in charcoal-stripped medium with or without DHT were analyzed for AR-hnRNP H1 interaction by Co-IP analysis as shown above (n=3). C) Representative deconvolution photomicrographs (Leica DMRXA Deconvolution image depicting endogenous expression and colocalization of AR and hnRNP H1 in PC cells under DHT treated or deprived conditions for 2 hr. Cells were fixed and stained with Dapi nuclear counterstain (blue) and then reacted with hnRNP H1 or AR specific antibody followed by a secondary antibody conjugated with Alexa Fluor 488 (green) or Alexa Fluor 568 (red). Note hnRNP H1 is predominantly localized in the nucleus (white arrow), and weakly co-localizes with AR (yellow arrow) in absence of DHT. In contrast, DHT increases both expression and nuclear co-localization of hnRNP and AR (green arrow) in PC cells. Scale bar represents.
hnRNP H1 Mediates AR Binding to AREs on Target Genes in Hormone Dependent and Independent Fashion.
The hnRNP H1-AR physical interaction and its role in transcriptional regulation of PSA suggest that this NM protein possibly enhances AR binding to the AREs on ARGs. To this end, EMSA was employed to examine hnRNP H1 ability to modulate AR binding to three DIG-labeled ds oligonucleotides (oligo) encompassing the proximal promoter ARE-I (-170) and ARE-II (-394) and the enhancer element ARE-III (-4258) of PSA gene ( Figure 6A ). Nuclear extract (NE) proteins binding to all AREs on PSA gene was reduced (~ 50%) upon addition of anti-hnRNP H1 antibody ( Figure 7B ) in presence or absence of DHT ( Figure 6C and without DHT ( Figure 6D )-thus attesting to the possibility of hnRNP H1 binding to AR/ARE complex in vivo in a hormone-dependent and independent manner.
Next, we examined by ChIP analysis if hnRNP H1 binds AR/ARE complex in vivo. Whereas no binding was detected with control IgG, hnRNP H1 was found to be part of auxiliary protein binding complex in all PSA AREs examined under hormone-treated and, but to a lesser extent under DHT-deprived conditions in both AR-expressing PC cells ( Figure 6E ). Likewise, ChIP analysis demonstrates hnRNP H1 binding to AR on ARE-1 and ARE-2-containing exons D and E of the AR gene in both cell lines ( Figure 6F and G). Interestingly, we also observed hnRNP H1 binding to exon H but not to exon B of AG gene, both used as control non-ARE containing domains. Taken together, the results suggest a novel hormone-dependent and independent AR co-activation role for hnRNPH1, a previously uncharacterized mechanism in PC cells.
Task-2. To assess efficacy of down regulation of target gene(s) in inhibiting tumorigenic growth and metastatic potential of AA-derived CaP cells in vivo (Months 13-36).
-The tumorigenicity and metastatic potential of hnRNPH1 or SAFB2 shRNA-silenced PC cells in castrated or gonadally intact athymic mice in presence or absence of estrogen pellets will be examined.
In vivo xenograft model
Animal studies were performed in accordance with the Institution Animal Care and Use Committee (IACUC) at Tulane University. The androgen dependent LNCaP cells were transfected with control pcDNA3.1 or hnRNPH1 expression plasmid using Transfast TM Transfection Reagent (Promega Corp., WI). Stable cell clones were selected with 30µg/ml Geneticin (Invitrogen Corp., CA) and examined for hnRNPH1 expression by PCR and immunoblot analyses. Six week old BALB/cAnNCr-nu/nu mice were purchased from the Animal Genetics and Production Facility, Frederick, NCI, MD, USA. Xenografts were carried out by dual flank s.c. transplantation of 100 µl of cells (1 x 10 6 ) suspended in a mixture (1:1 ratio) of growth medium and Matrigel matrix (BD Biosciences). After 10 weeks, animals were sacrificed and weight and volume (W 2 × L)/2 formula) of resected tumors were measured.
As shown in Fig 8 (above) , tumor developed from hnRNPH1-transfected LNCaP cells were larger (> 2-fold) than control cells, suggesting that this nuclear matrix protein enhances growth of AR-expressing prostate tumor cells, even in the absence of the ligand. The results corroborate our in vitro studies.
Task-3. To establish the clinical utilities of target gene(s) as biomarkers and/or prognostic indicators of disease progression in AA men (Months 24-36).
Using NCI designed tissue microarrays and immunohistochemical (IHC) analysis; we will investigate if expression of target genes alone or in combination with hormone nuclear receptor (ER isoforms and AR) can serve as biomarkers or prognostic indictors of PC progression in AA men.
We have demonstrated that hnRNPH1 is selectively upregulated in prostate tumors men as opposed to normal glands or BPH regardless of race ( Fig 8) . Further analysis revealed higher expression of hnRNPH1 in prostate tumors of AA me in comparison to CA men (Fig 8) . 
Additional unplanned experiments
Upon submission of this manuscript to Nature Medicine Journal, the Editor asked for verification of our observation of selective expression of hnRNPH1 in prostate tumor of AA men, in comparison to CA men, in an independent cohort. They stressed that furnishing the data is critical prior to forwarding the manuscript to the reviewers. Accordingly, we analyzed hnRNPH1 gene expression in an independent prostate database in collaboration with Drs. Ambs and Hudson at the NIH. HNRNPH1 expression was explored in affymetix array data sets either downloaded from NCBI Geo or mined using oncomine (www.oncomine.com). First, we investigated HNRNPH1 expression from a data set (GSE17386) consisting of primary cell lines derived from prostate cancer epithelium of AA (n=14) and CA (n=13) cancer patients (Timofeeva et al., PMID: 19724911) . In this data set HNRNPH1 was increased (p<0.0005; 1.76 fold) in AA compared to EA derived tissues ( Fig. 10a ). HNRNPH1 expression was then evaluated in clinical tissue samples from the Wallace et al., dataset consisting of 20 non tumor and 69 tumor tissues (Wallace et al., PMID; 18245496). Here HNRNPH1 was increased in tumors versus non tumor tissues and to a greater extent in AA (p>0.0001) tumors then in CA tumors (p<0.018), when compared to non tumor tissues of the same ethnicity ( Fig. 10b and c) . These data support, in both an epithelium and mixed tissue background, that HNRHPH1 is evaluated in prostate cancer tissues and in those from AA men.
To test whether HNRNPH1 could be related to prostate cancer progression we next explored HNRNPH1 expression in association with Gleason sum score, and extraprostatic extension status where this information was available. In the Wallace et al. dataset HNRNPH1 expression was associated with higher Gleason sum score and extraprostatic extension positive tissues ( Fig. 10d and e). A similar finding was observed in an additional dataset from Glinsky et al, (PMID 1506732) where increases in HNRNPH1 expression were associated with increasing Gleason sum scores (Fig 2f) . Notably, in this dataset HNRNPH1 expression was also increased within samples from patients identified with recurrence at five years ( Fig.  10g ). Together these findings suggest an association for HNRNPH1 expression during the progression of prostate cancer. Further, a direct correlation of HNRNPH1 and AR expression (p<0.0001; Pearson r = 0.5174) and possible co-deregulation of these genes in prostate cancer tissues were observed in the Wallace et al data set, supporting a possible relationship between androgen signaling and HNRNPH1 expression ( Fig. 10h and i).
The editors also asked for potential mechanism involved in constitutive up-regulation of hnRNPH1 in prostate tumor cells, especially in AA men. To achieve this goal, we examined the potential roles of miRNA and methylation in transcriptional regulation of in prostate cancer cells, in which hnRNPH1 is constitutively upregulated, compared to control (RWPE1) cells.
miRNA may mediate selective HNRNPH1 upregulation in prostate tumors of AA men.
miRNAs has been recently shown to regulate expression of several key neoplastic-related genes in tumor cells. As such, we sought to unravel their role as an underlying mechanism for selective transcriptional upregulation of HNRNPH1 in prostate tumor cells of AA men in comparison to CA men. To achieve this goal, 24 flash-frozen, tumor grade-matched (Gleason 6) specimens (12 each from AA and CA men) were obtained from Louisiana Cancer Research Consortium (LCRC) tissue core facility. Frozen cryosections (6 µm thick) of each patient were prepared and matched normal and tumor cells were harvested by LCM and total RNA was extracted followed by cDNA synthesis. Comparative analysis of HNRNPH1-related miRNAs (GeneCards; MIR-22, MIR-122, MIR-132, MIR-181C, MIR-495 & MIR-505) in AA and CA LCM harvested tumor cells was performed using qPCR. While no significant difference was observed in the expression levels of MIR132, MIR-181C, MIR-495 and MIR-505, two of the HNRNPH1-related miRNAs (MIR-22 and MIR-122) were upregulated in tumor cells of AA men than CA men ( Fig 11) . The results suggest that higher expression MIR-22 and MIR-122 may be involved in transcriptional upregulation of HNRNPH1 in prostate tumor cells of AA men. 
Methylation may be responsible for upregulation of hnRNPH1 in tumor cells
Analysis of DNA methylation. We analyzed methylation of the HNRPNH1 promoter-CpG island by combined bisulfite restriction analysis (COBRA) and bisulfite sequencing by following the methods described in Borowczyk et al. 2009 . Briefly, ~1 µg each of genomic DNA from RWPE-1 and MDA PCa-2b cell lines was treated with bisulfite using the Epitect bisulfite kit (Qiagen, USA) and amplified with primers specific to different portions of the CpG island. Sequences of the PCR primers and the conditions for amplification are given in Supplementary Table 1 . The amplified products were purified from agarose gels using MinElute gel extraction kits, digested with BstUI and run on agarose gels to identify digestion fragments from the PCR products. For bisulfite genomic sequencing, PCR products were gel purified, cloned in PCRII-Topo vectors (Invitrogen, USA) and multiple recombinant clones were sequenced to identify methylated CpG sites.
5-Aza-2′-deoxycytidine treatment.
MDA PCa2b cells were grown to 30% confluence and were treated with 5-Aza-2′-deoxycytidine (Sigma, St Louis; final concentration = 2µM) for six days.
Results
We next studied whether the difference in the expression levels of HNRNPH1 between the MDA PCa-2b and RWPE-1 cell lines is associated with a difference in the level of methylation in the promoter-CpG island (Fig 1) . As shown in Fig 12A, HNRNPH1 promoter is embedded in a 1796 bp long CpG island. In order to scan this entire region for DNA methylation combined bisulfite restriction analysis (COBRA) was used. For this purpose, bisulfite PCR reactions were designed to amplify six overlapping regions within the CpG island ( Supplementary table 1 ). DNA samples from MDA PCa-2b and RWPE-1 cell lines were converted with bisulfite and amplified with specific primers as mentioned above. The PCR products were digested with BstUI and resolved on agarose gels to identify potential regions that show a difference in the levels of DNA methylation. In these experiments, presence of digestion products indicates methylation of the region amplified by the primers. The results of COBRA shown in Fig 1B suggest that region f (hg19:chr5:179051441-179051688, Fig 12A) is more methylation in MDA Pca-2b cell line than in RWPE-1 cell line. The amount of digestion is also consistent with the expectation that this region is about 50% methylated in MDA PCa-2b cell line and in RWPE-1 cell line, it is more or less unmethylated. The COBRA results were validated by bisulfite genomic sequencing, in which multiple clones from the bisulfite PCR products from the two cell lines were sequenced and the number of CpGs methylated in the cloned products was determined for each CpG site ( Fig 12C, 1D ). The results summarized in Fig 1D suggest that 14 out of 19 CpG sites investigated show >25% increase in methylation in DNA from MDA PCa-2b cell line. This difference in methylation suggests as positive correlation between DNA methylation in this region and HNRNPH1 expression. To test this possibility, MDA PCa2b cells were treated with 5-Aza-2′-deoxycytidine for six days and RNA samples were prepared from the treated cells and untreated control cells. HNRNPH1 transcript levels were estimated by qRT-PCR using GAPDH as internal control. When the data were normalized against GAPDH, we observed ~1.7-fold decrease in the level of HNRPN1 transcript levels in the cells treated with 5-Aza-2′deoxycytidine. Taken together, these results suggest that methylation of the proximal portion of the promoter CpG island is associated with transcription of HNRPNH1. of the HNRPNH1 promoter-CpG island in MDA PCa-2b and RWPE-1 cell lines. About half of the product from region f is digested by BstUI in MDA PCa-2b but not in RWPE-1, suggesting that this region is hypermethylated in the former. No significant difference was observed for the other regions. U: unmethylated DNA, M: fragments from methylated DNA. For more details on fragment sizes for all the regions, see Supplementary Table 1 . (C) Bisulfite genomic sequencing of region f from MDA PCa-2b and RWPE-1. This region (247 bp) contains 19 CpGs shown as vertical lines at the top. Twelve clones from RWPE-1 and 18 clones from MDA PCa2 were sequenced. Methylated CpGs are shown as filled circles and unmethylated CpGs as clear circles. (D) Summary of bisulfite genomic sequencing data for the two cell lines. Fourteen out of 19 CpGs studied show more than 25% increase in methylation for MDA PCa2b cell line. (E) qRT-PCR analysis of GAPDH and HNRNPH1 in untreated MDA PCa2b control cells and cells treated with 5-Aza-2′-deoxycytidine (Deaza).
Discussion
DNA methylation is generally thought to be associated with gene repression. However, a recent report showed that gene body methylation prevents CTCF-mediated repression of BCL6 promoter (PMID 20733034) in B cell lymphoma cells and suggested that methylation of these CpG sites have a positive role on BCL6 transcription. In the methylation and gene experiments described here for MDA PCa-2b and RWPE-1 cell lines, we observed methylation of an upstream region of the HNRNPH1 promoter CpG island and overexpression in MDA PCa-2b cells. To our knowledge, this is the first example in which methylation of an upstream element has a positive effect on gene transcription.
Key Research Accomplishments:
We demonstrate selective expression of the nuclear matrix protein heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1) in nuclei of PC cells that correlate with disease progression and poor prognosis in AA men in two independent cohorts. hnRNP H1 siRNA silencing conferred growth arrest and sensitized androgen receptor (AR)-expressing PC cells to bicalutamide. Functional studies demonstrate that hnRNP H1 physically interacts with and induces AR transactivation in hormone dependent and independent manner. The transcriptional upregulation of AR and PSA genes by hnRNP H1 was coupled with an increase in AR binding to its cognate DNA element on PSA promoter and exonic domains within the AR gene. In addition, we demonstrate that MIR-22 and MIR-122 may be involved in transcriptional upregulation of HNRNPH1 in tumor cells of AA men as opposed to CA men. Additionally, we also demonstrate that promoter methylation may be involved in constitutive expression of this nuclear matrix protein in prostate tumor cells.
Reportable Outcomes:
Presentaions:
The outsome of the study was presented orally (invited speaker) at the Innvovative Minds in Prostate Cancer Today (IMPact) meeting in FL, March 9-12, 2011.
Manuscript will be submitted to Nature Medicine.
The Editors suggested that additional experiments are needed to warrant review. These include verification of our observations in an independent cohort (or database) and characterization of underlying mechanisms involved in upregulation of HNRNPH1 expression in prostate tumor cells of AA men. Both of these requests were experimentally documented in this report. The editors also asked for in vivo studies to verify our in vitro findings. These experiments are underway and are expected to be completed in the next few months. Once completed, the manuscript will be re-submitted to Nature Medicine for publication.
Conclusions: African Americans (AA) have twice the incidence and mortality of prostate (PC) than Caucasian Americans (CA). While the disproportionate burden was partially explained by genetic, socioeconomic, and environmental factors, racial variation in the biology of prostate tumors was not investigated. We employed an unbiased functional genomics approach to identify genes differentially expressed in freshly procured prostate tumor cells of age-and tumor gradematched AA and CA men. Laser capture microdissected (LCM)-procured in vivo-derived genetic materials of matched normal epithelium and PC cells were subjected to suppressive subtractive hybridization (SSH) to construct microarray chips encompassing two sets of race-based, PCspecific cDNAs. Verification and functional assays were performed by standard techniques. We demonstrate selective expression of the nuclear matrix protein heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1) in nuclei of PC cells that correlate with disease progression and poor prognosis in AA men. These findings were verified via an independent cohort of PC patients. A correlation between MIR-22 and MIR-122 expression and selectivel upregulation of hnRNPH1 in prostate tumor cells was established. siRNA silencing of hnRNPH1 conferred growth arrest and sensitized androgen receptor (AR)-expressing PC cells to bicalutamide. Functional studies demonstrate that hnRNP H1 physically interacts with and induces AR transactivation in hormone dependent and independent manner. The transcriptional upregulation of AR and PSA genes by hnRNP H1 was coupled with an increase in AR binding to its cognate DNA element on PSA promoter and exonic domains within the AR gene. The findings support a model in which hnRNP H1 is an auxiliary coactivator for ligand-dependent and independent transactivation of AR in tumor cells. Our data further demonstrate a previously uncharacterized mechanism for AR-hnRNP H1 axis in disease progression and development of hormone refractory PC in AA men.
Racial make-up has been identified as one of many risk factors for PC with more than 50% higher incidence and mortality rates among AA men than CA counterparts (1). Earlier onset of the disease, high disease volume, aggressive metastatic disease, and poor survival rate are evident among AA males (2, 3) . Although the disproportionate incidence and mortality cannot be fully explained by genetic, socioeconomic, and environmental factors (4, 5) , chromosome 8q24 has recently been implicated in susceptibility but not the aggressiveness of PC in AA men (6, 7) . While a more biological aggressive phenotype has been proposed (8), little attention was focused on unraveling the underlying molecular mechanisms involved in racial disparity of PC.
As a residual scaffolding of the nucleus to which repeated DNA sequences and actively transcribed genes are anchored (11), the nuclear matrix (NM), has recently sparked a surge of interest as being the molecular underpinning of cancer-specific markers (12) . The family of heterogeneous nuclear ribonucleoproteins (hnRNPs) has more than 30 members of ubiquitously expressed NM proteins (13) . hnRNPs complex with heterogeneous nuclear RNA (hnRNA) and modulate pre-mRNA biogenesis, metabolism, and transport (14) . The hnRNP H/F is subfamily of hnRNPs encoded by different genes into subtype-naïve forms, including hnRNP H (hnRNP H1), hnRNP H' (hnRNP H2), hnRNP F, and hnRNP 2H9 (15) . These proteins possess a modular and highly conserved structure encompassing two glycine-rich auxiliary domains and two or three repeats of RNA binding domain termed quasi-RNA recognition motif (qRRM). The hnRNP H/F members bind in concert to cognate G-rich intronic and exonic sequences in close proximity to the polyadenylation site to regulate both inhibitory and stimulatory alternative splicing of target genes (16) . As a bona fide component of the NM, (17) , the functional significance of hnRNP H1 is relatively unknown and only recently has evidence emerged related to its biological function. Although hnRNP H1 has been shown to be expressed in a number of human cancers (18) , its functional significance in cancer development and/or progression has not been elucidated. The rapid reduction of hnRNP H1 transcripts in cells undergoing differentiation (19) underscores a potential role for this NM protein in tumor cell differentiation.
RESULTS
Strategy to identify PC differentially expressed genes in AA men
The functional genomics approach employed for identification of differentially expressed genes is schematically depicted (Supplementary Fig. 1a) . Each cell population harvested by LCM was estimated to be >99% homogeneous as determined by microscopic visualization of the captured cells (Supplementary Fig. 1b) . Our PCR analysis of cDNAs before and after RsaI digestion and efficiency of adaptor ligation in forward hybridizations demonstrated that SSH analysis was carried out successfully ( Supplementary Fig. 2 ) Subsequent cloning of cDNAs (200-900 bp) resulted in generation of SSH library ~1,500 race-related PC-specific cDNAs of unknown identity (Supplementary Fig. 3) . The SSH cDNA libraries were exploited to custom construct cDNA array chip encompassing two super-grids of 750 PC-specific genes each for AA and CA patients. Initial hybridization analysis revealed that the custom arrays are reproducible and yield high signal to noise ratios.
Microarray screening and data analysis
An RNA in vitro transcription strategy was employed to generate sufficient cRNA for microarray analysis. Total RNA was linearly amplified with T7 polymerase so that population skewing and the loss of quantification are minimal (20) . Our use of aminoallyl derivatives obviates some of the complications generally seen in direct fluorescent labeling. Following image acquisition and normalization, the degree of variability and reproducibility among analyzed samples of various datasets was assessed. Statistical linear regression of Cy3 against Cy5 and the linear regression of log ratio against average intensity (MA plots) were used for Within-Array normalization (Fig.  1a) . Box-plot method for Between-Array normalization was used for comparing the distributions of log intensities or log ratios of genes on different arrays (Fig. 1b) . With these approaches, minimal variability in gene expression was observed between normalized hybridizations.
hnRNP H1 expression correlates with disease progression in AA men
The differential gene expression profile analysis in AA and CA groups was approached as a collection of tests for each gene based on the "null hypothesis" of no difference or, alternatively, as estimating the probability that a gene shows differential expression using t-test statistic criterion at 5% level. Our custom race-, PC-specific cDNA microarray and sequencing analyses revealed differential yet significant expression of a number of genes (Fig. 1c) . The hnRNP H1 was on the top of highly expressed genes (p<0.001) in AA prostate tumors compared to CA men. qRT-PCR analysis of in LCM-harvested cells showed a 6-fold (p<0.001) and 3-fold (p<0.05) increase in hnRNP H1 transcript levels in AA and CA prostate tumors, respectively, when compared to the matched normal epithelium in each group (Fig. 1d ). TMA analysis corroborated these findings (Fig. 2m) , with predominant and intense hnRNP H1 immunoreactivity in the nuclei of tumor cells in AA men (Fig. 2g,h,i) in comparison to BPH (Fig. 2d,e, f) , neighboring stroma, and normal epithelium (Figure 3, A, B , and C). Of the clinicopathological variables studied (Supplementary Table 1) , the hnRNP H1 score positively correlated with Gleason score in both race groups (Fig. 2n) . Consistent with the comparative qRT-PCR analysis, the hnRNP H1 protein expression was found to be significantly higher (p<0.01) in moderately differentiated (Gleason 6-7) tumors in AA men compared to CA men (Fig. 2n) . In addition a correlation between hnRNP H1 staining and PSA recurrence-free was observed in AA men as opposed to CA men, suggesting a trend towards poor prognostic outcome in this ethnic group of patients (data not shown).
hnRNP H1 siRNA-silencing induces growth arrest and sensitizes AR-expressing PC cells to bicalutamide
The basal transcript expression levels of hnRNP H1 was 3-and 6-fold higher (p<0.01) in ARexpressing MDA-PCa-2b and C4-2B cells, respectively, with predominant nuclear localization compared to the AR(-) PC-3 cells (Fig. 3a,b) . The selective expression of hnRNP H1 in ARexpressing cells was further corroborated by TMA-4 IHC analysis where higher nuclear immunostaining was observed in LNCaP cells (Fig. 2l) compared to PC-3 cells (Fig. 3k) . Accordingly, MDA-PCa-2b and C4-2B cells were then exploited as a model to unravel the functional significance of hnRNP H1 in the AR-mediated prostate tumor cell growth and drug resistance.
Next, we examined by siRNA strategy whether hnRNP H1 is critical to proliferation of MDA-PCa-2b and PC-3 cells. Transfection, as optimized by GFP and siGLO Lamin A/C duplex siRNA, demonstrates > 95% transfection and silencing efficiencies in both cell lines (Fig. 3c,d) .
The hnRNP H1 siRNA down-regulated the target gene by at least 90% as opposed to cells transfected with non-targeting siControl duplexes (Fig 3e,f) . As shown in Figure 4g , a significant (p<0.05) time-dependent growth inhibition was observed as early as 48 hr in MDA-PCa-2b cells transfected with hnRNP H1 siRNA in comparison to untrasfected or siControl transfected cells. In contrast, the growth kinetics was not affected in response to target gene silencing in AR-naïve PC-3 cells under similar experimental conditions (Supplementary Fig. 4) .
Since androgen deprivation is the mainstay therapy for locally advanced and CRPC, we sought to examine whether modulation of endogenous hnRNP H1 levels would impact the sensitivity and/or therapeutic efficacy of the non-steroidal anti-androgen bicalutamide (BIC) in PC cells. MDA-2B-PCa and C4-2B cells pre-transfected with hnRNP H1 siRNA or siControl were subjected to various concentration of BIC in presence of dihydrotestosterone (DHT) or vehicle control. hnRNP H1 siRNA-silenced MDA-PCa-2b and C4-2B cells were sensitive to BIC cytotoxicity at 10 µM in absence and presence of DHT in cells (p<0.05) (Fig. 3h,i) , suggesting a role for this NM protein in development of antiandrogen drug resistance.
hnRNP H1 confers androgen dependent and independent transactivation of the AR in PC cells
The growth inhibitory effects caused by hnRNP H1 siRNA silencing in MDA-PCa-2b cells prompted us to investigate whether these effects are mediated through modulation of AR activation. As shown in Figures 3j and 3k , hnRNP H1 induced hormone-independent AR activation in AR-transfected COS-7 and CV-1 cells when compared to negative controls or cells transfected with wtAR or hnRNP H1 alone (p<0.05). Likewise, transfection of C4-2B cells with hnRNP H1 caused AR transactivation in a ligand-independent manner (Fig. 3l) . In contrast, DHT induced almost twice the level of AR activation following ectopic co-expression of hnRNP H1 and AR in COS-7 and CV-1 cells (Fig. 3j.k) and hnRNP H1-transfected C4-2B cells (Fig. 3l) as opposed either factor alone (p<0.05). Interestingly, DHT in absence of AR significantly increased (p<0.05) PSA promoter activity in hnRNP H1-transfected COS-7 and CV-1 cells. (Fig. 3j,k) . Finally, these findings were confirmed by silencing hnRNP H1 in MDA-C4-2B cells with or without DHT (Fig. 3m) .
hnRNP H1 physically interacts with AR and regulates transcription of androgen regulated genes in PC cells
The activation of AR by hnRNP H1 prompted us to investigate if these proteins physically interact in PC cells. Analysis of PC cell lysates immunoprecipitated (IP) with anti-hnRNP H1 demonstrates an increase in immunoblotted AR levels (Fig. 4a) . Conversely, immunoblotted hnRNP H1 increased in cell lysates reciprocally IP with AR antibody in comparison to control rabbit IgG, suggesting protein-protein interaction. The AR-hnRNP H1 interaction was further augmented in DHT-treated cells (Fig. 4b) . Immunocytochemical analysis demonstrated that the interacting proteins are primarily co-localized in the nucleus even in the absence of DHT, an effect that was enhanced by of DHT (Fig. 4c) .
Based on its role in mRNA biogenesis and AR interaction, we examined if endogenous expression of hnRNP H1 modulates transcriptional regulation of AR and ARGs in PC cells. qRT-PCR analysis reveals that siRNA silencing of hnRNP H1 (Fig. 4d,e ) was coupled with a significant reduction in the basal transcript levels of PSA ( Fig. 4f,g) and AR (Fig. 4h,i) under both DHT treatment and deprived conditions (p<0.05). These findings were confirmed by immunoblot analysis (Fig. 4j,k) . In contrast, DHT increased nuclear hnRNP H1 protein levels in both cell lines (Fig. 4j,k) , suggesting a positive feedback regulatory loop between androgens and hnRNP H1 in the transcriptional regulation of AR and PSA genes in PC cells.
hnRNP H1 mediates AR binding to AREs on target genes in ligand dependent and independent fashion
The hnRNP H1-AR physical interaction and its role in transcriptional regulation of PSA suggest that this NM protein possibly enhances AR binding to the AREs on ARGs. To this end, EMSA was employed to examine hnRNP H1 ability to modulate AR binding to three DIG-labeled ds oligonucleotides (oligo) encompassing the proximal promoter ARE-I (-170) and ARE-II (-394) and the enhancer element ARE-III (-4258) of PSA gene (Fig. 5a) . Nuclear extract (NE) proteins binding to all AREs on PSA gene was reduced (~ 50%) upon addition of anti-hnRNP H1 antibody (Fig. 6b) in presence or absence of DHT ( Fig. 6c) in MDA-PCa-2b cells. Moreover, siRNA silencing of hnRNP H1 reduced such ARE binding with and without DHT (Fig. 6d) , attesting to the possibility of hnRNP H1 binding to AR/ARE complex in vivo in a hormonedependent and independent manner.
Next, we examined by ChIP analysis if hnRNP H1 binds AR/ARE complex in vivo. Whereas no binding was detected with control IgG, hnRNP H1 was found to be part of auxiliary protein binding complex in all PSA AREs examined under hormone-treated and, but to a lesser extent under DHT-deprived conditions in both AR-expressing PC cells (Fig. 5e) . Likewise, ChIP analysis demonstrates hnRNP H1 binding to AR on ARE-1 and ARE-2-containing exons D and E of the AR gene in both cell lines (Fig. 6f,g) . Interestingly, we also observed hnRNP H1 binding to exon H but not to exon B of AG gene, both used as control non-ARE containing domains. Taken together, the results suggest a novel hormone-dependent and independent AR co-activation role for hnRNP H1, a previously uncharacterized mechanism in PC cells.
DISCUSSION
Differences in underlying biological mechanisms have been proposed as a possible explanation of the disproportionate burden and progression of PC in AA men (8) . However, elucidation of molecular events underlying the progression of PC in AA men has been hampered by the limitations inherent to both in vitro and in vivo experimental approaches. Our comparative in vivo gene expression profile analysis represents the first study of its kind where an integrated unbiased functional genomics approach encompassing a combined LCM/SSH on fresh specimens for custom construction of race-based, PC-specific DNA oligo arrays to examine whether AA men have unique in vivo gene expression profile compared to age and tumor stagematched CA men.
Several lines of evidence lend credence to the fact that PC transforms more rapidly from an indolent to an aggressive phenotype in AA than CA men (21) . In this study, we demonstrated, for the first time, selective expression of hnRNP H1 in nuclei of moderately differentiated tumor cells (Gleason score 6) in comparison to normal epithelium, stromal cells, and BPH in both populations, but with higher expression in AA than CA men. It is noteworthy that the elevated levels of hnRNP H1 were found to be correlated with Gleason score and possibly with poor clinical outcome in AA men. Additional studies will be needed to determine the relevance of these findings to prognosis. Consistent with our finding is that the elevated expression of hnRNP H1 has been shown predominantly in the nuclei of several human cancers, including, adenocarcinoma of the pancreas, hepatocellular carcinoma, gastric carcinoma, and head and neck cancer (18) . In addition, tumor immunobiological differences were reported in AA and CA men (22) . Interestingly, a recent study demonstrated selective expression and correlation of hnRNP K with Gleason score and poor prognosis in PC patients (23) . Thus, the unique expression profile of this NM protein in prostate tumor cells of AA men not only attests to racial differences in biology of PC, but may also account in part to its potential role in disproportionate incidence and mortality of the disease in this ethic group of patients. Taken together, hnRNP H1 may have potential clinical utility as a biomarker, prognostic indicator, and/or therapeutic target in the management of PC.
The molecular mechanism(s) involved in transcriptional regulation of hnRNPs remain largely unknown (24) . In the present study we demonstrate aberrant expression of hnRNP H1 in AR-expressing, but not AR naïve, PC cells. The results also suggest that hnRNP H1 may be a transcriptional target of DHT/AR in prostate tumor cells presumably through putative ARE on the promoter region. Alternatively, transcriptional upregulation may be regulated through hnRNP H1 promoter DNA elements, including E2F, AP1, acute myeloid leukemia (AML), and c-myc (24) . This notion is strengthened by the fact that hnRNP H1 transcripts are differentially upregulated in SV40 transformed cells in comparison to normal cells (15) .
hnRNP H1 is one of the lesser known members of the hnRNP family in terms of its biological functions. In this study we demonstrated that siRNA silencing of hnRNP H1 inhibits growth of AR-expressing but not AR non-expressing PC cells in vitro, suggesting activation of AR signaling is critical in part to its growth stimulatory effects. This notion is further strengthened by the fact that hnRNP H1 require AR, regardless of its mutation status, to induce ligand dependent and independent activation of PSA promoter. In agreement with our findings, ectopic expression of hnRNP K has been shown to enhance cell proliferation and anchorageindependent growth of breast cancer cells (25) . In contrast to hnRNP H1 action, hnRNP A1 has been shown to inhibit PC cell growth through suppression of ARA54-enhanced AR transactivation (26) , indicating that some members of hnRNP family have mutually antagonistic effects on tumor cell growth. Taken together, we report here, for the first time, a new role for hnRNP H1 in ligand-dependent and independent transcriptional regulation of androgen regulated genes in PC cells.
The mutations, aberrant expression of AR gene, and activation of AR signaling have been implicated in growth and metastasis of PC and correlates with PSA elevation (27) . Here we report that hnRNP H1-induced AR activation is associated with both ligand dependent and independent transcriptional up-regulation of AR and PSA genes in PC cells. Our finding that hnRNP H1 transcripts are upregulated by DHT thus suggests a positive feedback loop between AR and this NM protein. The results document, for the first time, a previously uncharacterized mechanism for hnRNP H1 in mediating selective transactivation of AR and aberrant expression of AR and ARGs in an androgen-dependent and independent manner. The hnRNP H1's role in activation of AR signaling thus represents a novel mechanism by which prostate tumor cells may escape androgen dependence in AA men.
That a number of coregulators interact directly or indirectly with AR and modulate its activity (28) prompted us to speculate that hnRNP H1 possibly mediate its ARGs promoter activation through AR binding. To this end, we demonstrated physical interaction between hnRNP H1 and AR, predominantly in the nuclei of PC cells. In agreement with our findings, direct cell-free binding studies showed the prostate NM to have acceptor sites for high AR binding (29) . Regardless of hormone stimulation status, our EMSA and ChIP analyses revealed that hnRNP H1-AR binding was primarily observed on all AREs on the promoter and enhancer domains of the PSA gene and selective ARE-containing exons on AR gene, suggesting it may act as a coactivator of AR in PC cells. Our findings were corroborated by reports that AR coactivator Tip60, which is up-regulated by androgen deprivation therapy, has been shown to be recruited to the promoter of the PSA in the absence of androgens (30) . In addition, AR coactivators SRC-1 and TIF-2 have been shown to be up-regulated in tissue specimens of patients who failed PC endocrine therapy and that their selective expression is coupled with enhanced activation of the AR signaling in tumor cells (31) . Taken together, our reporter assays coupled with physical interaction AR and selective ARE binding suggest a coactivation role for hnRNP H1 in AR regulation of ARGs in PC cells under hormone induced and deprived conditions.
We also observed AR-independent induction of PSA promoter activity by hnRNP H1 in the presence of DHT, indicating it may directly bind specific DNA sequences to regulate transcription. This finding is in line with the fact that hnRNP H1 is implicated as a trans-acting factor by direct binding to DNA sequences (16) and estrogen response element (32) . This newly identified functional role for hnRNP H1 was also exhibited by other hnRNP family members, such as hnRNP A1 (33) and hnRNP K (34, 35) . Moreover, several hnRNP family members have been shown to bind DNA Matrix Attachment Regions (MARs), a specific chromatin DNA sequences that interact with NM and initiate transcription (36) . Thus hnRNP H1 binding to MARs may potentially modulate the chromatin state and induce transcription of ARGs possibly via modifications of RNA complexes and protein-protein interaction. Whether selective binding by DHT of the NM or nuclear ribonucleoprotein particles, leads to AR-independent transactivation of ARGs certainly warrant further investigation.
The nonsteroidal antiandrogen BIC is often used as monotherapy or in combination with androgen deprivation therapy (37) for locally advanced or biochemically recurrent PC to prevent androgen dependent activation of the AR and upregulation of ARGs (38) by binding to and accelerating degradation of the AR in tumor cells (39) . Although this treatment regimen initially exhibits favorable responses, PC inevitably becomes refractory and develops resistance to BIC (40) . As a suppressor of AR transcription and activation, we demonstrate that hnRNP H1 silencing sensitizes PC cells to the BIC-mediated growth arrest under DHT-deprived conditions-thus further augmenting AR-dependent growth inhibition by BIC in PC cells. This effect was partially ameliorated by DHT in AR-expressing, suggesting that hnRNP H1 overexpression may be associated with development of resistance to hormonal therapy via up-regulation of AR transcripts and amplification of AR signaling in tumor cells. Thus, targeting of hnRNP H1 may represent a novel form of hormone sensitization-based therapy in the clinical management of androgen-dependent and CRPC.
In conclusion, our study paves the way for further understanding of the complexity of the biology and molecular mechanisms involved in the disparity of PC. Given heterogeneity of PC and that AR is implicated in development of CRPC, the results suggest that selective expression of hnRNP H1 in a subset of tumor cells in AA men may confer disease progression and development of therapeutic resistance via enhancing transcription and activation of AR in a ligand dependent and independent manner. The hnRNP H1-AR axis may thus represent a previously unknown mechanism for disease progression, and development of hormone refractory disease in this ethnic group of patients. The results not only implicate racial differences in the biology of PC, but also suggest, for the first time, a new frontier for the development of diagnostic, preventive, and/or targeted therapeutic strategies to circumvent disease in this ethnic group of patients.
METHODS
Patients and prostate cancer specimens
Fresh, flash-frozen specimens were obtained from age-(50 to 60 yrs) and tumor grade-matched (Gleason score 6) AA and CA prostate cancer patients. All patients received no prior therapy, presented with palpable prostate tumors, and underwent radical prostatectomy. Following surgical removal of the prostate, part of the specimens were excised, embedded in Tissue-Tek ® OCT Compound (Jed Pella Inc., Redding, CA), snap-frozen in liquid nitrogen, and stored at -80ºC until processing. In addition, histopathological sections were made from the rest of the specimens for confirmation, staging, and grading of PC. IRB approval was obtained prior to conducting the experiments.
LCM and RNA preparation
Using a Minotome Plus TM cryostat microtome (Triangle Biomedical Sciences, Inc., Durham, NC), frozen specimens were sectioned (6 µm thick), mounted onto uncoated glass slides, and store in -80ºC until used. For LCM, frozen sections were thawed at room temperature for 10 s, fixed in 70% ethanol for 10 s, and stained in Hematoxylin (40 s), bluing solution (20 s) and Eosin (20 s), followed by dehydration twice in 95% ethanol and 100% ethanol for 15 s. The sections were then incubated in Xylene, air dried, and microdissected using PixCell II system and CapSure LCM caps (Arcturus Engineering, Mountain View, CA, USA). Using replica sections, matched normal prostate epithelium and tumor cells in each section were LCM procured using 2,000~3,000 pulses, spot diameter of 15 µm, and 25-35 mwatt laser power. Total RNA was extracted from pooled captured cells in a 500 µl nuclease-free Eppendorf tube containing 400µl of TRI Reagent (Molecular Research Centre, Inc., Cincinnati, OH) mixed with 1µl of 10µg/µl of RNA carrier GenElute TM Linear Polyacrylamide (Sigma, St. Louis, MO), as per manufacturer's instructions. After recovery of RNA pellet, a DNase treatment step was performed for 2 hr at 37°C using 2 unit of RQ1 RNase-free DNase (Promega Corporation, Madison, WI), followed by re-extraction and precipitation. The RNA yield and integrity were determined using Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA) with RNA LabChip (Ambion Inc., Austin, TX, USA).
Construction of race-based PC-specific SSH cDNA libraries
First-strand cDNA synthesis was performed according to the SMART TM PCR cDNA Synthesis kit (Clontech Laboratories, Inc., Palo Alto, CA). For the long-distance (LD)-PCR, 200ng of total RNA from matched LCM captured prostate tumor cells or normal prostate epithelium of each section were reverse transcribed using CDS primer (5'-AAGCAGTGGTAACAACGCAGA GTACT (30) N -1 N-3') and SMART II oligonucleotide (5'-AAGCAGTGGTAACAACGCAGAG TACGCGGG-3'). The first-strand cDNAs were amplified by 18 to 22 cycles of LD-PCR, as determined by the parallel control tubes, and then purified by ammonium chloride-ethanol precipitation method followed by RsaI digestion to generate shorter, blunt-ended ds cDNA fragments. The purified cDNAs were dissolved with 1 × TE buffer a final concentration of 300 ng/µl. The SSH analysis was performed using CLONTECH PCR-Select TM cDNA Subtraction kit (Clontech Laboratories, Inc., Palo Alto, CA). Briefly, the cDNAs of normal prostate cells (driver) and tumor cells (tester) were subjected to forward and reverse subtractions. Using T4 DNA ligase, aliquots of the tester cDNAs were ligated to Adaptor1 and Adaptor 2R separately. Ligation efficiency was performed using G3PDH 3' primer and PCR primer 1 followed by two rounds of hybridization. In the first hybridization, the RsaI-digested driver cDNA was mixed with either Adaptor1-ligated tester cDNA or Adaptor2R-ligated tester cDNA. In the second hybridization the two reactions from the first hybridization were mixed and processed for a second hybridization in the presence of freshly denatured driver cDNAs to further enrich the differentially expressed transcripts. The missing strands of the adaptors were then filled to create a template for PCR primer 1. To enrich the differentially expressed target sequences, PCR amplification was performed using nested PCR primers 1 and 2R (5'-TCGAGCGGCCGCCCGGGCAGGT-3'; 5'-AGCGTGGTCGCGG CCGAGGT-3') using 10-12 cycles of 94°C for 10 s (denaturing), 68°C for 30 s (annealing), and 72°C for 1.5 min (extension). Subtraction efficiency analysis was determined using β-actin to confirm the reduced relative abundance of the housekeeping gene after SSH. The SSH nested PCR products were cloned using pCR  2.1 vector TA Cloning  Kit (Invitrogen TM Life Technologies, Carlsbad, CA). Hundreds of colonies were analyzed for DNA inserts by direct colony PCR using M13 forward and reverse amplimer set and high fidelity platinum Taq  DNA polymerase (Invitrogen TM Life Technologies, Carlsbad, CA) in a thermal cycle conditions of 95°C, 5 min (denaturing) followed by 30 cycles of 94°C for 30 s, 48°C for 30 s, and 72 °C for 2 min (annealing/extension), and a final extension at 72°C for 7 min. The PCR products were resolved onto a 1.2% agarose/EtBr gel and fragment sizes of less than 200 bp or multiple bands were considered negative and were excluded from study.
Custom construction of race-based PC-specific cDNA array chips
To generate PC-specific cDNA arrays for AA and CA patients, PCR amplification of the selected clones was carried out using nested PCR primers in 96-well plates then purified by Montage TM The thermal cycle conditions included a denaturing step at 94°C, 2 min; followed by 27 cycles of 94°C for 10 s, 68°C for 30 s, and 72 °C for 1.5 min, and by the final extension repair at 72°C for 7 min. The products were resolved onto 1.2% agarose/EtBr and the nested PCR products were then purified by Montage TM PCR 96 Cleanup Kit (Millipore Corporation, Bedford, MA). Briefly, MultiScreen 96 PCR plates containing nested PCR products were cleaned using a vacuum manifold, then washed once with 100 µl of H 2 O. Samples were eluted in nuclease-free water and transferred to the 384-well plates. DNA concentrations were determined spectrophotometrically and plates were then lyophilized and tightly sealed. For microarray spotting, the cDNAs (750/race group) were individually reconstituted in 150 mM phosphate buffer (pH 8.5) with a DNA concentration of 1 µg/ml. Each cDNA was subsequently printed (Virtek Chipwriter Pro) and pooled to construct two supergrids (one for AA and another for CA) onto GAPS II amino-silane coated glass slides (Corning Inc, Corning, NY). The microarray printer relies on Telechem split pin technology to deliver equally sized spots with low variability of DNA concentration. Additionally, negative and positive controls (housekeeping genes) from the Ambion™ ArrayControls™ Set were included, and each cDNA on the array was double spotted for reliable data interpretation.
Gene array analysis
Total RNA isolated from LCM-procured normal epithelium and tumor cells from flash-frozen sections of matched (50 to 60 yrs; Gleason score 6) tissue sections of AA and CA patients was amplified using MessageAmp TM aRNA Kit according with the manufacturer's instruction (Ambion Inc., Austin, TX). Microarray probes were prepared by in vitro RNA transcription followed by reverse transcription of the aRNA in presence of aminoallyl-dUTP, and coupled to Cyanine-3 (Cy3) or Cyanine-5 (Cy5) dye. Briefly, 200 ng of RNA was mixed with T7 Oligo(dT) primer, denatured at 70°C and snap cool on dry ice. Reverse transcription master mix was then added and subsequently incubated at 42°C for 2 hr in an air incubator. The in vitro aRNA transcription step was performed using MEGAscript  T7 High-yield Transcription Kit at 37°C overnight in an air incubator. The amplified RNA was then treated with DNase I to remove the cDNAs and subsequently purified using RNeasy  Micro Kit (Qiagen, Inc., Valencia, CA). A second round of amplification was performed using second round primers as shown above. The final concentration of aRNA was determined spectrophotometrically and its quality was determined by denatured RNA gel electrophoresis. The aRNA was then aliquoted and stored at -80°C until for microarray analysis. Probe preparation was performed by reverse transcribing 5 µg of aRNA in presence of 6 µg of random primers (Invitrogen TM Life Technologies, Carlsbad, CA), 500 µM each of dATP, dCTP, and dGTP, 200 µM of 5-aminoallyl-dUTP (Ambion Inc., Austin, TX), 300 µM of dUTP, 10 mM dithiothreitol, and 400 unit of Superscript II (Invitrogen TM Life Technologies, Carlsbad, CA) at 42°C for 3 hours. The reaction was stopped by addition of EDTA and NaOH followed by heating at 65°C for 15 min; reactions were then neutralized with HCl. The cDNA was purified using QiaQuick PCR Purification Kit (Qiagen, Inc., Valencia, CA), vacuum-dried, and resuspended in sodium carbonate buffer (pH 9.0). The coupling reaction was performed by addition of NHS ester of Cy3 or Cy5 dye (Amersham Pharmacia Biotech Inc., Piscataway, NJ) at RT for 1 hr in the dark, quenched by the addition sodium acetate (pH 5.2), and the unincorporated dye was removed using QIAquick PCR Purification Kit. The labeled cDNAs were vacuum-dried, re-suspended in 1× SlideHyb buffer (Ambion Inc., Austin, TX), mixed (1:1 ratio) and stored at -70 o C until used.
The custom race-, PC-based cDNA microarray slides were re-hydrated over steam of boiled water for 5 sec and then dried on a heat block for 5 sec. After UV cross-linking, the slides were washed in 1% SDS for 2 min, incubated in 95°C water for 2 min, dipped in 95% ethanol 20 times, and spun dry by centrifugation. For hybridization, probes prepared from normal and prostate tumors of each patient was denatured at 98°C, mixed at 1:1 ratio and loaded onto the slide in an automated GeneTAC TM Hybridization station (Genomic Solutions Inc., Ann Arbor, MI). An over-night step-down temperature hybridization program (65 o C for 3 hr with agitation; 55 o C for 3 hr with agitation; 50 o C for 12 hr with agitation) was performed followed by medium-(2 cycles at 55 o C), high-stringency (2 cycles at 42 o C), and post-wash buffer (2 cycles at 42 o C) washes. The hybridized slides were scanned by GeneTAC TM UC-IV microarray scanner (Genomic Solutions Inc., Ann Arbor, MI, USA). The quality of the images and visualization of the spatial homogeneity of the hybridization was assessed by histogram plots techniques. The foreground spot intensities formed the primary data for all subsequent analyses and were corrected by subtracting the background intensities. All spots with background intensities higher than the foreground intensity were excluded.
Tissue microarray (TMA) analysis
Differential expression of hnRNP H1 in prostate tumor cells was validated by immunohistochemical (IHC) analysis using an ethnicity-based TMA (TMA-4). Designed by the National Cancer Institute (NCI), TMA-4 provides high statistical power to investigate possible differences in PC marker prevalence between AA and CA men. The tissue cores of TMA-4 include 4 neoplastic tissue samples from each of 150 AA and CA biopsies, 17 BPH cores, 13 normal cores, and 3 cell line cores (LNCaP, DU-145, PC-3) on each side of the 4-slide set. The clinical annotation and array maps of the TMA can be retrieved at http://cpctr.cancer.gov/cpctr_tma.html#tma2 and Supplementary Table 1 .
For IHC analysis, the TMA slides were deparaffinized, rehydration, and immunostained using Biocare reagents in a Biocare Nemesis 7200 automated system (Biocare Medical, Concord, CA). The endogenous biotin and H 2 O 2 were quenched by sequential incubation in 3% H 2 O 2 (5 min) and avidin-biotin blocking solution (10 min). Antigen retrieval was achieved by incubation in Biocare BORG solution and the non-specific sites were blocked by Sniper block solution for 10 minutes, followed by addition of anti-hnRNP H1 antibody (1:2,000) (Bethyl Laboratories, Inc. Montgomery, TX) for 45 min. The hnRNP H1 antibody is highly specific since it was raised against a peptide representing a portion of the C-terminus. The antigen-antibody complex was revealed using secondary and tertiary HRP-conjugated antibodies (10 min each) and visualized by beta-DAB substrate-chromagen solution for 1 min. The slides were then counterstained by hematoxylin and blueing solution and dried up for mounting. For negative controls, the entire IHC method was performed on sections in the absence of primary antibody.
The TMA slides were independently examined and scored under light microscopy by two pathologists (B.E.C. and K.M.), who were blinded to all clinical information as described (41, 42) . The extent of immunoreactivity in tumor and adjacent non-tumor cells was graded using a two-score system. In the first score system, the prostate tumor cell staining intensity of hnRNP H1 in each tissue core was assigned a score of 0=0 (no staining); 1=1+ (weak); 2=2+ (moderate); and 3=3+ (strong). In addition, the antigen expression was designated a score of 0 to 3 (0=0%; 1=<25%; 2=25-50%; or 3= >50%) based on the percentage of stained tumor cells in each of these categories of tissue microarray cores examined. The score of cells in each stain-intensity category was multiplied by the corresponding percent staining to obtain a score on a scale of 0 to 9; (0 = no staining; 1-2 = weak; 3-6 = moderate; 7-9 = strong staining). In the second score system, the antigen staining was scored +1, 0, or -1 if intensity in tumor glands was greater, equal or less than the adjacent normal tissue, respectively. A net immunoscore value was obtained by adding the scores of the two systems to give a final value ranging from 0 to10. The final score of the AA and CA tissue cores was expressed as Mean ± SE.
Cell lines and plasmids
All cell lines were obtained from American Type Culture Collection and maintained at 37°C in a humidified atmosphere at 5 % CO 2 . PC-3 was cultured in F-12K medium (Invitrogen Corporation, Carlsbad, CA) whereas COS-7 and CV-1, an SV40 transformed African green monkey kidney cells were maintained in DMEM (GIBCO). MDA-PCa-2b, an AA bone marrowderived metastatic PC cell line, was maintained in BRFF-HPC1 medium (Athena Environmental Sciences, Inc, Baltimore, MD) supplemented with 20% FBS and 50 µg/ml gentamicin. C4-2B cells, an isogenic subline of LNCaP cells obtained from Dr. L. W. Chung (Emory University, Atlanta, GA), was cultured in RPMI medium supplemented with 10% FBS. Unless otherwise indicated, all cells were cultured in RPMI medium supplemented with 10% FBS for comparative analysis while DHT treated PC cells were cultured in phenol red-free RPMI-1640 media supplemented with 10% charcoal stripped FBS (Atlanta Biologicals, Lawrenceville, GA), and antibiotics.
The human hnRNP H1 expression plasmid, pcDNA3.1/V5-His-TOPO-HNRPH1, was constructed by subcloning a cDNA of the hnRNP H1 gene (Genbank accession # BC001348) into a pcDNA3.1/V5-His-TOPO  expression kit in accordance with the manufacturer's instructions (Invitrogen TM Life Technologies, Carlsbad, CA). cDNAs derived from hnRNP H1expressing MDA-PCa-2b cells was used as a template to amplify a 1373 bp fragment encompassing the OFR of the gene with 30 PCR cycles using a primer set (sense, 5'-GTAAGAGACGATGTTGGG-3'; antisense 5'-GCTCCTTGGTTACCTATGC-3') a highfidelity platinum  Taq DNA polymerase (Invitrogen TM Life Technologies, Carlsbad, CA) at 94°C for 1 min (denaturing), 53°C for 1 min (annealing) and 70°C for 2 minutes (extension). The target sequence was amplified by PCR and fused in-frame into a pcDNA3.1/V5-His  TOPO  TA expression plasmid to generate pCMV-hnRNP H1. Insertion and orientation of DNA was verified by colony PCR, restriction digest map, and PCR amplification using hnRNP H1 specific sense primer and the plasmid flanking BGH reverse primer. The pcDNA3.1(+)AR (pCMV-AR), a human wt-AR expression plasmid was kindly provided by Dr. X-B Shi (University of California at Davis). The supra PSA/pGL3-luc (psPSA-luc), a luciferase reporter gene driven by truncated PSA promoter sequences encompassing AREs, was obtained from Dr. L. W. Chung (Emory University).
Quantitative RT-PCR
Briefly, RNA was extracted from matched LCM procured normal epithelium and tumor cells of age-, tumor grade-matched flash-frozen sections (n=24) of AA and CA patients using Tri-Reagent kit and subsequently reverse transcribed using SuperScript II RT and oligo dT primers. First-strand cDNAs were then analyzed by qRT-PCR using specific amplimer set for hnRNP H1 and β-actin genes (Icycler iQTM, Bio-Rad, Hercules, CA). The primers were designed using Primer Express Software Version 2.0 (Applied Biosystems) ( Supplementary Table 2 ) and were PCR amplified using a SYBR GREEN PCR Master Mix and iTaq TM DNA polymerase at 95°C 5 min for 1 cycle followed by 40 cycles of denaturation at 95°C for 30 s, annealing at 60°C for 30 s, and extension 72°C for 30 s, and a final hold at 72°C for 10 min.
In another set of in vitro experiments in PC cells the expression of hnRNP H1, AR and PSA was quantified by qRT-PCR analysis ( Supplementary Table 2 ). Briefly, total RNA was extracted and purified with an RNeasy kit (Qiagen, Inc., Valencia, CA) and 2 µg was reverse transcribed using an ImProm-II™ Reverse Transcription System (Promega). qRT-PCR was performed with SYBR green reagent (Bio-Rad, Hercules, CA) using 10 ng template in a 25 µl reaction mixture. The primer pair mix for AR (43) and PSA (44) were PCR amplified using a SYBR Green PCR master mix and iTaq TM DNA polymerase at 95°C 3 min, 1 cycle; followed by 40 cycles of denaturation at 95°C for 15 s, annealing at 55°C for 45 s, and extension at 72°C for 90 s, followed by a final hold at 72°C for 10 min. The primer specificity for each gene was determined by a melting curve graph using selected max emission dye family fluorophore FAM-490. Serial dilutions of the input samples were used to make a standard curve. Data was analyzed using the comparative C T method and the amount of each amplicon was normalized to a housekeeping gene, β-actin or GAPDH. Gene expression was calculated using CFX-qPCR Version 1.5 (Bio-Rad, Hercules, CA). Data was represented by three independent experiments in triplicates for each treatment condition and primer set. (e,f) Endogenous mRNA and proteins levels of hnRNP H1, respectively, at 24 hr following siRNA transfection. (g) Assessment of growth inhibitory effects by a cell counting assay kit in hnRNP H1 siRNA-silenced MDA-PCa-2b cells cultured in complete medium for up to 120 hr. (h,i) Cell growth of MDA-PCa-2b and C4-2B cells, respectively, pre-transfected with siControl or hnRNP H1 siRNA and cultured in RPMI containing charcoal-stripped serum and various concentrations of BIC with (+) or without (-) DHT for 24 hr (n=3). (j,k) COS-7 and CV-1 cells, respectively, were cultured in charcoalstripped FBS medium in absence (ethanol) or presence of DHT and co-transfected with hnRNP H1, pCMV-AR, and psPSA-Luc plasmids. (l) C4-2B cells co-transfected with hnRNP H1 and psPSA-Luc plasmids and cultured with or without DHT. (m) C4-2B cells co-transfected with siControl or siRNPH1 and psPSA-Luc reporter and cultured with or without DHT. For normalization all cells were co-transfected with 5 ng pRL-SV40. Activity was measured with dual luciferase system and the results were expressed as fold change of relative light units (RLU). * and ** denotes significant difference at p<0.05 and p<0.01, respectively, in comparison to controls (n=3). (a) PC cell lysates cultured in complete medium were subjected to immunoprecipitation (IP) using anti-AR or anti-hnRNP H1 antibody, followed by immunoblotting (IB) with the indicated antibodies in a reversed order as shown. (b) Lysates of PC cells cultured in charcoal-stripped medium with or without DHT were analyzed for AR-hnRNP H1 interaction by Co-IP analysis as shown above (n=3). (c) Representative deconvolution photomicrographs (Leica DMRXA Deconvolution image depicting endogenous expression and co-localization of AR and hnRNP H1 in PC cells under DHT treated or deprived conditions for 2 hr. Cells were fixed and stained with Dapi nuclear counterstain (blue) and then reacted with hnRNP H1 or AR specific antibody followed by a secondary antibody conjugated with Alexa Fluor 488 (green) or Alexa Fluor 568 (red). Note hnRNP H1 is predominantly localized in the nucleus (white arrow), and weakly colocalizes with AR (yellow arrow) in absence of DHT. In contrast, DHT increases both expression and nuclear co-localization of hnRNP and AR (green arrow) in PC cells. Scale bar represents 10 µm. qRT-PCR analysis of hnRNP H1 (d,e), PSA (f,g), and AR (h,i) transcripts in MDA-PCa-2b and C4-2B cells, respectively, cultured in phenol red-free, charcoal-stripped media and transfected with siControl (non-target siRNA) or hnRNP H1 siRNA (siRNP H1) with or without DHT (n=3). Immunoblot analysis of PSA, AR and hnRNP H1 in hnRNP H1 siRNA-silenced (siRNPH1) or siControl-transfected MDA-PCa-2b (j) and C4-2B (k) cells, respectively, with or without DHT. The purity of nuclear and cytoplasmic fractions was assessed by TATA binding protein (TBP) and α-tubulin, respectively, whereas actin was used as a loading control (n=3). * and ** denotes statistical significant difference at p<0.05 and p<0.01, respectively. 
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